These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

66 related items for PubMed ID: 21424131

  • 1. Acute application of cisplatin affects methylation status in neuroblastoma cells.
    Tabata K, Sakai H, Nakajima R, Saya-Nishimura R, Motani K, Okano S, Shibata Y, Abiko Y, Suzuki T.
    Oncol Rep; 2011 Jun; 25(6):1655-60. PubMed ID: 21424131
    [Abstract] [Full Text] [Related]

  • 2. New insights into neuroblastoma cisplatin resistance: a comparative proteomic and meta-mining investigation.
    D'Aguanno S, D'Alessandro A, Pieroni L, Roveri A, Zaccarin M, Marzano V, De Canio M, Bernardini S, Federici G, Urbani A.
    J Proteome Res; 2011 Feb 04; 10(2):416-28. PubMed ID: 21128686
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells.
    Qiu YY, Mirkin BL, Dwivedi RS.
    Cancer Detect Prev; 2005 Feb 04; 29(5):456-63. PubMed ID: 16185816
    [Abstract] [Full Text] [Related]

  • 4. Impact of cisplatin administration on protein expression levels in renal cell carcinoma: a proteomic analysis.
    Vasko R, Mueller GA, von Jaschke AK, Asif AR, Dihazi H.
    Eur J Pharmacol; 2011 Nov 16; 670(1):50-7. PubMed ID: 21924258
    [Abstract] [Full Text] [Related]

  • 5. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
    Ibanez de Caceres I, Cortes-Sempere M, Moratilla C, Machado-Pinilla R, Rodriguez-Fanjul V, Manguán-García C, Cejas P, López-Ríos F, Paz-Ares L, de CastroCarpeño J, Nistal M, Belda-Iniesta C, Perona R.
    Oncogene; 2010 Mar 18; 29(11):1681-90. PubMed ID: 20023704
    [Abstract] [Full Text] [Related]

  • 6. Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance.
    Wermann H, Stoop H, Gillis AJ, Honecker F, van Gurp RJ, Ammerpohl O, Richter J, Oosterhuis JW, Bokemeyer C, Looijenga LH.
    J Pathol; 2010 Aug 18; 221(4):433-42. PubMed ID: 20593487
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
    Verrills NM, Po'uha ST, Liu ML, Liaw TY, Larsen MR, Ivery MT, Marshall GM, Gunning PW, Kavallaris M.
    J Natl Cancer Inst; 2006 Oct 04; 98(19):1363-74. PubMed ID: 17018783
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Intrinsic cisplatin resistance in lung and ovarian cancer cells propagating in medium acutely depleted of folate.
    Whiteside MA, Piyathilake CJ, Bushell TM, Johanning GL.
    Nutr Cancer; 2006 Oct 04; 54(2):274-84. PubMed ID: 16898872
    [Abstract] [Full Text] [Related]

  • 12. Proteomic analysis of the basic proteins in 5-fluorouracil resistance of human colon cancer cell line using the radical-free and highly reducing method of two-dimensional polyacrylamide gel electrophoresis.
    Tanaka S, Sakai A, Kimura K, Yoshida H, Fushitani H, Ogata A, Miyamoto A, Fukushima M, Wada A, Tanigawa N.
    Int J Oncol; 2008 Aug 04; 33(2):361-70. PubMed ID: 18636157
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A proteomic kinetic analysis of IGROV1 ovarian carcinoma cell line response to cisplatin treatment.
    Le Moguen K, Lincet H, Marcelo P, Lemoisson E, Heutte N, Duval M, Poulain L, Vinh J, Gauduchon P, Baudin B.
    Proteomics; 2007 Nov 04; 7(22):4090-101. PubMed ID: 17994630
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Potent anticancer activity of pyrrolidine dithiocarbamate-copper complex against cisplatin-resistant neuroblastoma cells.
    Zhang H, Wu JS, Peng F.
    Anticancer Drugs; 2008 Feb 04; 19(2):125-32. PubMed ID: 18176108
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
    Jiao JW, Wen F.
    Oncol Rep; 2011 Mar 04; 25(3):781-8. PubMed ID: 21165580
    [Abstract] [Full Text] [Related]

  • 19. Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles.
    Iwasaki I, Sugiyama H, Kanazawa S, Hemmi H.
    Cancer Chemother Pharmacol; 2002 Jun 04; 49(6):438-44. PubMed ID: 12107547
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.